switching from tirzepatide to retatrutide vs. going from tirzepatide to retatrutide

Abdel Aziz MT, Mostafa T, Atta H, Wassef MA, Fouad HH, Rashed LA, et al

Here's the kicker though, BPC-157 has NO FDA APPROVAL for any medical use in humans

CRB-601: Anti-Integrin Monoclonal Antibody We entered into a license agreement (the UCSF License Agreement) with the Regents of the University of California (The Regents) effective May 26, 2021, as amended to include additional inventions effective November 17, 2022, and further amended to include certain new technology rights effective August 14, 2023

A multidistrict litigation (MDL) shares some similarities with a class action, but they are legally distinct processes

And I couldnt be happier

The key point is that the mechanism discussion is tied to a defined copper peptide